NCT05086445 is a Phase 1 clinical trial of LY3502970 in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company.

Who is sponsoring NCT05086445?

NCT05086445 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT05086445?

Interventions in NCT05086445: LY3502970, Placebo.

What condition does NCT05086445 study?

NCT05086445 studies Diabetes Mellitus, Type 2.

Is NCT05086445 still recruiting?

NCT05086445 is currently completed. Last updated 28 November 2022.

Last reviewed 2022-11-28 · How we verify

NCT05086445

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

Completed Phase 1 Last updated 28 November 2022

What this trial tests

Phase 1 trial testing LY3502970 in Diabetes Mellitus, Type 2 in 62 participants. Completed in 5 September 2022.

Timeline

12 November 2021

Primary endpoint
5 September 2022

5 September 2022

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	62
Start date	12 November 2021
Primary completion	5 September 2022
Estimated completion	5 September 2022
Sites	5 locations across Japan

Drugs / interventions tested

LY3502970 — full drug profile →
Placebo

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

Adults 20 to 70, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last up to 24 weeks, inclusive of screening and will include 10 visits to the study center.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Signaling pathways in obesity: mechanisms and therapeutic interventions.
Wen X, Zhang B, Wu B, Xiao H, et al · · 2022 · cited 245× · PMID 36031641 · DOI 10.1038/s41392-022-01149-x
A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes.
Ohwaki K, Nakamura C, Nasu R, Takenouchi K, et al · · 2026 · cited 1× · PMID 41325139 · DOI 10.1111/jdi.70157

Verify or expand the search:

Other trials of LY3502970

Trials testing the same drug.

NCT06085482 — A Phase I Study of LY3502970 in Healthy Participants · Phase 1 · completed
NCT06023095 — A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities · Phase 1 · completed
NCT05936138 — A Study of LY3502970 in Participants With Normal and Impaired Renal Function · Phase 1 · completed
NCT05882032 — A Study of LY3502970 in Participants With Impaired and Normal Liver Function · Phase 1 · completed
NCT05841238 — A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants · Phase 1 · completed

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05086445 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 28 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05086445.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing